Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT04416984
Trial Phases:	Phase I Phase II	Protocol IDs:	ALLO-501A-201 (primary) NCI-2020-04325
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Allogene Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT04416984

Summary

This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in
adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess
the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or
refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with
relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.